Drug Type Small molecule drug |
Synonyms R3R 01 |
Target |
Mechanism ABCA1 stimulants(ATP binding cassette subfamily A member 1 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Albuminuria | Phase 2 | DK | 18 Sep 2024 | |
Diabetic Nephropathies | Phase 2 | DK | 18 Sep 2024 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | US | 15 Jun 2022 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | BE | 15 Jun 2022 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | FR | 15 Jun 2022 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | DE | 15 Jun 2022 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | NL | 15 Jun 2022 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | GB | 15 Jun 2022 | |
Nephritis, Hereditary | Phase 2 | US | 15 Jun 2022 | |
Nephritis, Hereditary | Phase 2 | BE | 15 Jun 2022 |